Moderna, Inc.
MRNA Healthcare Biotechnology
Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024. In the quarter to June 2026, revenue grew 2.11%, EPS grew 7.51%, free cash flow grew 38.9% and total debt rose 1,765.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100.
Follow MRNA
Moderna, Inc. (MRNA) EBITDA
Moderna, Inc.'s EBITDA for fiscal 2025 was −$2.9B, compared with −$3.9B in fiscal 2024. Over the twelve months to 30 June 2026 it was −$3.1B. Over the past ten years it has ranged from −$3.9B (fiscal 2024) to $13.6B (fiscal 2021); the current reading is higher than 30% of that period. Moderna, Inc. ranks 600th of 600 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$2.9B | — |
| FY2024 | −$3.9B | — |
| FY2023 | −$3.7B | — |
| FY2022 | $9.8B | (27.85%) |
| FY2021 | $13.6B | — |
| FY2020 | −$722.0M | — |
| FY2019 | −$519.0M | — |
| FY2018 | −$390.3M | — |
| FY2017 | −$247.7M | — |
| FY2016 | −$206.2M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$762.0M | — |
| Mar 2026 | −$1.3B | — |
| Dec 2025 | −$803.0M | — |
| Sep 2025 | −$225.0M | — |
| 30 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| VRTX Vertex Pharmaceuticals Incorporated compare | $5.0B |
| REGN Regeneron Pharmaceuticals, Inc. compare | $4.4B |
| ARGX argenex SE compare | $1.6B |
| RPRX Royalty Pharma PLC compare | $1.5B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $1.1B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $1.1B |
| ROIV Roivant Sciences Ltd. compare | −$593.3M |
| RVMD Revolution Medicines, Inc. compare | −$1.6B |
| MRNA Moderna, Inc. | −$3.1B |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on MRNA
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement